Preeclampsia is a pregnancy-related disorder characterized by hypertension (HTN) with unclear mechanism. Studies have shown endothelial dysfunction and increased endothelin-1 (ET-1) levels in hypertensive-pregnancy (HTN-Preg). ET-1 activates endothelin receptor type-A (ETAR) in vascular smooth muscle to induce vasoconstriction, but the role of vasodilator endothelial ETBR in the changes in blood pressure (BP) and vascular function in HTN-Preg is unclear. To test if downregulation of endothelial ETBR expression/activity plays a role in HTN-Preg, BP was measured in Norm-Preg rats and rat model of HTN-Preg produced by reduction of uteroplacental perfusion pressure (RUPP), and mesenteric microvessels were isolated for measuring diameter, [Ca2+]i, and ETAR and ETBR levels. BP, ET-1 and KCI-induced vasoconstriction and [Ca2+]i were greater in RUPP than Norm-Preg rats. Endothelium-removal or microvessel treatment with ETBR antagonist BQ-788 enhanced ET-1 vasoconstriction and [Ca2+]i in Norm-Preg, but not RUPP, suggesting reduced vasodilator ETBR in HTN-Preg. ET-1+ETAR antagonist BQ-123, and ETBR agonists sarafotoxin 6c (S6c) and IRL-1620 caused less vasorelaxation and nitrate/nitrite production in RUPP than Norm-Preg. The NOS inhibitor L-NAME reduced S6c- and IRL-1620-induced relaxation in Norm-Preg but not RUPP, supporting that ETBR-mediated NO pathway is compromised in RUPP. RT-PCR, Western blots and immunohistochemistry revealed reduced endothelial ETBR expression in RUPP. Infusion of BQ-788 increased BP in Norm-Preg, and infusion of IRL-1620 reduced BP and ET-1 vasoconstriction and [Ca2+]i and enhanced ETBR-mediated vasorelaxation in RUPP. Thus downregulation of microvascular vasodilator ETBR is a central mechanism in HTN-Preg, and increasing ETBR activity could be a target in managing preeclampsia.